Novo Nordisk A/S Common Stock (NY:NVO)

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗

Topics Government World Trade

November 07, 2025

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Via Benzinga

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Topics Government

Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗

November 06, 2025

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

Topics Government

November 06, 2025

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

Topics Government World Trade

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗

November 06, 2025

Via Benzinga

Topics Government

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗

November 06, 2025

Is the fourth time the charm for this Danish pharmaceutical giant?

The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.

Topics Earnings

Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗

November 06, 2025

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

Topics Government

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits ↗

November 06, 2025

Via Benzinga

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal ↗

November 06, 2025

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.

Via Benzinga

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further ↗

November 06, 2025

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera ↗

November 06, 2025

Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

Novo Nordisk (NVO) exemplifies affordable growth investing with strong expansion, reasonable valuation, high profitability, and a solid dividend.

Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy ↗

November 06, 2025

Via Chartmill

Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes ↗

November 06, 2025

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.

Via Benzinga

Topics Government

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal ↗

November 05, 2025

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Topics Law Enforcement

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

Via MarketMinute

Topics Economy

Novo Nordisk Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Novo Nordisk reported third-quarter financial results on Wednesday. The transcript from the company's earnings call has been provided below.

Via Benzinga

Topics Earnings

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...

Via MarketMinute

Topics Economy Intellectual Property Supply Chain

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗

November 05, 2025

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Via Benzinga

Prediction: Novo Nordisk Will Soar by 2026 ↗

November 05, 2025

Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the biggest pharma rebounds of 2026.

The Wegovy and Ozempic maker cut its 2025 sales outlook for the third time.

Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year ↗

November 05, 2025

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗

November 05, 2025

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs ↗

November 05, 2025

Via Benzinga

Here's Why Shares in Viking Therapeutics Shot Higher in October ↗

November 05, 2025

Three factors took Viking's shares higher in the month.

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap? ↗

November 05, 2025

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.